SENS PubMed Publication Search
Targeting p21 Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity
Cell Metab. 2022 Jan 4;34(1):75-89.e8. doi: 10.1016/j.cmet.2021.11.002.
Lichao Wang 1, Binsheng Wang 1, Nathan S Gasek 1, Yueying Zhou 2, Rachel L Cohn 1, Dominique E Martin 3, Wulin Zuo 4, William F Flynn 4, Chun Guo 5, Evan R Jellison 6, Taewan Kim 3, Larissa G P Langhi Prata 7, Allyson K Palmer 7, Ming Li 8, Christina L Inman 7, Lauren S Barber 5, Iman M A Al-Naggar 5, Yanjiao Zhou 9, Wenqiang Du 10, Kshitiz 10, George A Kuchel 5, Alexander Meves 8, Tamar Tchkonia 7, James L Kirkland 7, Paul Robson 11, Ming Xu 12
Abstract:
Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2 diabetes. Limited mechanism-based strategies exist to alleviate insulin resistance. Here, using single-cell transcriptomics, we identify a small, critically important, but previously unexamined cell population, p21Cip1 highly expressing (p21high) cells, which accumulate in adipose tissue with obesity. By leveraging a p21-Cre mouse model, we demonstrate that intermittent clearance of p21high cells can both prevent and alleviate insulin resistance in obese mice. Exclusive inactivation of the NF-κB pathway within p21high cells, without killing them, attenuates insulin resistance. Moreover, fat transplantation experiments establish that p21high cells within fat are sufficient to cause insulin resistance in vivo. Importantly, a senolytic cocktail, dasatinib plus quercetin, eliminates p21high cells in human fat ex vivo and mitigates insulin resistance following xenotransplantation into immuno-deficient mice. Our findings lay the foundation for pursuing the targeting of p21high cells as a new therapy to alleviate insulin resistance.
PMID: 34813734
Free Full-Text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732323/
Tags: Insulin resistance, mice, NF-kB, obesity, p21, senolytics